JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M206330200 on October 8, 2002

J. Biol. Chem., Vol. 277, Issue 49, 47136-47148, December 6, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/49/47136    most recent
M206330200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Badran, B. M.
Right arrow Articles by Willard-Gallo, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badran, B. M.
Right arrow Articles by Willard-Gallo, K. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification of Three NFAT Binding Motifs in the 5'-Upstream Region of the Human CD3gamma Gene That Differentially Bind NFATc1, NFATc2, and NF-kappa B p50*

Bassam M. BadranDagger , Steven M. Wolinsky§, Arsène BurnyDagger , and Karen E. Willard-GalloDagger

From the Dagger  Laboratory of Experimental Hematology, Faculty of Medicine, University of Brussels, 121 Blvd. de Waterloo, Brussels B1000, Belgium and the § Division of Infectious Diseases, Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611

Human immunodeficiency virus, type 1 (HIV-1) infection of CD4+ T cells progressively abrogates T cell receptor (TCR)·CD3 function and surface expression by specifically interfering with CD3gamma gene transcription. Our data show that the loss of CD3gamma transcripts begins very early after infection and accumulates to a >90% deficiency before a significant effect on surface receptor density is apparent. Blocking TCR·CD3-directed NFAT activation with cyclosporin A provokes a partial re-expression of CD3gamma gene transcripts and surface complexes in a time- and dose-dependent manner. We have identified three NFAT consensus sequences (5'-GGAAA-3') in the 5'-upstream region of the human CD3gamma gene at: -124 to -120 (NFATgamma 1), -384 to -380 (NFATgamma 2), and +450 to +454 (NFATgamma 3) from the first transcription initiation site. Using electrophoretic mobility shift and supershift assays, we show that NFATc2 alone binds to the NFATgamma 2 motif; however, complexes containing either NFATc2 or NFATc1 plus NF-kappa B p50 bind to the NFATgamma 1 and NFATgamma 3 sites. We further demonstrate that NFATc1 and NF-kappa B p50 bind in the same protein·DNA complex and that a fourth Ala added to the core sequence (5'-GGAAAA-3') in NFATgamma 1, and NFATgamma 3 is critical for their binding. Finally, we have shown that an increase in the binding of nuclear NFATc2, NFATc1, and NF-kappa B p50 to these three motifs is correlated with a progressive loss of CD3gamma transcripts after HIV-1 infection.


* This work was supported by grants from the Belgian Fonds National de la Recherche Scientifique (FNRS-FRSM Grant 3.4584.01 and FNRS-Télévie Grants 7.4554.01 and 7.4584.01), the European Commission (Grant QLK2-2000-01040), the National Institutes of Health (Grant HD37356), and a collaborative grant from the International Brachet Foundation (Grant R 97/8-05).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Tel.: 32-2-541-3739; Fax: 32-2-541-3453; E-mail: kwillard@ulb.ac.be.


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
Y. Tone, Y. Kojima, K. Furuuchi, M. Brady, Y. Yashiro-Ohtani, M. L. Tykocinski, and M. Tone
OX40 Gene Expression Is Up-Regulated by Chromatin Remodeling in Its Promoter Region Containing Sp1/Sp3, YY1, and NF-{kappa}B Binding Sites
J. Immunol., August 1, 2007; 179(3): 1760 - 1767.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Cardoso, V. Durbecq, J.-F. Laes, B. Badran, L. Lagneaux, F. Bex, C. Desmedt, K. Willard-Gallo, J. S. Ross, A. Burny, et al.
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
Mol. Cancer Ther., December 1, 2006; 5(12): 3042 - 3051.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. M. Badran, K. Kunstman, J. Stanton, M. Moschitta, A. Zerghe, H. Akl, A. Burny, S. M. Wolinsky, and K. E. Willard-Gallo
Transcriptional Regulation of the Human CD3{gamma} Gene: The TATA-Less CD3{gamma} Promoter Functions via an Initiator and Contiguous Sp-Binding Elements
J. Immunol., May 15, 2005; 174(10): 6238 - 6249.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.